The Journal of Immunology, Vol 156, Issue 10 3579-3582, Copyright © 1996 by American Association of Immunologists

CUTTING EDGE

Commentary: Novel vaccine approaches

HC Ertl and Z Xiang
Wistar Institute, Philadelphia, PA 19104, USA.

Recent advances in immunology, molecular biology, and peptide biochemistry have allowed the construction of subunit vaccines based on viral or bacterial recombinants, peptides or plasmid vectors. Although none of these approaches is currently being used for mass vaccination (with the exception or vaccinia-rabies G protein recombinant virus for wildlife immunization); several of them are undergoing clinical trials. None of these different vaccine constructs is likely to be totally effective in either the prevention of infectious diseases or immunotherapy of cancer. Recombinant viral vaccines such as those based on vaccinia or adenovirus as a rule induce potent immune responses. Vaccinia viruses have the added advantage of being heat stable and immunogenic after oral application, making them good candidates for wildlife immunization. Recombinants based on replication-defective adenoviruses are safer compared with vaccinia virus recombinants and, as far as our data indicate, have superior efficacy. In addition, they induce excellent immunity upon application to mucosal membranes, suggesting their usefulness as vaccines for infectious agents that enter through the airways or the genital tract. Peptides are of limited benefit in infectious disease prevention but might provide custom-made vaccines for cancer therapy. Genetic vaccines that were first described less than 5 years ago have already progressed to phase I clinical trials in healthy human adults. Provided that their safety can be confirmed, they might be suited to induce immunity to numerous agents.

This article has been cited by other articles:

				J.-R. Yu, S. Kim, J.-B. Lee, and J. Chang Single Intranasal Immunization with Recombinant Adenovirus-Based Vaccine Induces Protective Immunity against Respiratory Syncytial Virus Infection J. Virol., March 1, 2008; 82(5): 2350 - 2357. [Abstract] [Full Text] [PDF]

				J. Charo, J. A. Lindencrona, L.-M. Carlson, J. Hinkula, and R. Kiessling Protective Efficacy of a DNA Influenza Virus Vaccine Is Markedly Increased by the Coadministration of a Schiff Base-Forming Drug J. Virol., October 15, 2004; 78(20): 11321 - 11326. [Abstract] [Full Text] [PDF]

				J. Charo, M. Sundback, K. Wasserman, A.-M. T. Ciupitu, B. Mirzai, R. van der Zee, and R. Kiessling Marked Enhancement of the Antigen-Specific Immune Response by Combining Plasmid DNA-Based Immunization with a Schiff Base-Forming Drug Infect. Immun., December 1, 2002; 70(12): 6652 - 6657. [Abstract] [Full Text] [PDF]

				P. Riedl, S. El Kholy, J. Reimann, and R. Schirmbeck Priming Biologically Active Antibody Responses Against an Isolated, Conformational Viral Epitope by DNA Vaccination J. Immunol., August 1, 2002; 169(3): 1251 - 1260. [Abstract] [Full Text] [PDF]

				J. D. Harris, I. R. Graham, S. Schepelmann, A. K. Stannard, M. L. Roberts, B. L. Hodges, V. Hill, A. Amalfitano, D. G. Hassall, J. S. Owen, et al. Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1-, E3-, polymerase-] adenovirus vector expressing human apoE Hum. Mol. Genet., January 1, 2002; 11(1): 43 - 58. [Abstract] [Full Text] [PDF]

				P. L. Ogra, H. Faden, and R. C. Welliver Vaccination Strategies for Mucosal Immune Responses Clin. Microbiol. Rev., April 1, 2001; 14(2): 430 - 445. [Abstract] [Full Text] [PDF]

				A. Zakhartchouk, C Pyne, G. Mutwiri, Z Papp, M. Baca-Estrada, P Griebel, L. Babiuk, and S. Tikoo Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1 J. Gen. Virol., May 1, 1999; 80(5): 1263 - 1269. [Abstract]

				A Sanz-Parra, B Vazquez, F Sobrino, S. Cox, V Ley, and J. Salt Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins J. Gen. Virol., March 1, 1999; 80(3): 671 - 679. [Abstract]

				H. G. A. Bouwer, H. Shen, X. Fan, J. F. Miller, R. A. Barry, and D. J. Hinrichs Existing Antilisterial Immunity Does Not Inhibit the Development of a Listeria monocytogenes-Specific Primary Cytotoxic T-Lymphocyte Response Infect. Immun., January 1, 1999; 67(1): 253 - 258. [Abstract] [Full Text] [PDF]

				D. H. Barouch, S. Santra, T. D. Steenbeke, X. X. Zheng, H. C. Perry, M.-E. Davies, D. C. Freed, A. Craiu, T. B. Strom, J. W. Shiver, et al. Augmentation and Suppression of Immune Responses to an HIV-1 DNA Vaccine by Plasmid Cytokine/Ig Administration J. Immunol., August 15, 1998; 161(4): 1875 - 1882. [Abstract] [Full Text] [PDF]

				S. Chun, M. Daheshia, N. A. Kuklin, and B. T. Rouse Modulation of Viral Immunoinflammatory Responses with Cytokine DNA Administered by Different Routes J. Virol., July 1, 1998; 72(7): 5545 - 5551. [Abstract] [Full Text] [PDF]

				K. Jooss, Y. Yang, K. J. Fisher, and J. M. Wilson Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers J. Virol., May 1, 1998; 72(5): 4212 - 4223. [Abstract] [Full Text] [PDF]

				J. D. Ballard, A. M. Doling, K. Beauregard, R. J. Collier, and M. N. Starnbach Anthrax Toxin-Mediated Delivery In Vivo and In Vitro of a Cytotoxic T-Lymphocyte Epitope from Ovalbumin Infect. Immun., February 1, 1998; 66(2): 615 - 619. [Abstract] [Full Text] [PDF]

				T. Tuting, C. C. Wilson, D. M. Martin, Y. L. Kasamon, J. Rowles, D. I. Ma, C. L. Slingluff Jr., S. N. Wagner, P. van der Bruggen, J. Baar, et al. Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN-{alpha} J. Immunol., February 1, 1998; 160(3): 1139 - 1147. [Abstract] [Full Text] [PDF]